Interchange Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$682K Buy
5,395
+2,341
+77% +$308K 0.13% 162
2026
Q1
$380K Sell
3,054
-1,106
-27% -$155K 0.12% 176
2025
Q4
$511K Buy
4,160
+1,049
+34% +$127K 0.09% 194
2025
Q3
$345K Buy
+3,111
New +$354K 0.07% 244
2025
Q2
Sell
-1,888
Closed -$212K 294
2025
Q1
$212K Buy
1,888
+30
+2% +$3.1K 0.06% 255
2024
Q4
$172K Hold
1,858
0.06% 245
2024
Q3
$156K Sell
1,858
-511
-22% -$39K 0.05% 255
2024
Q2
$163K Buy
+2,369
New +$158K 0.06% 259
2023
Q2
Sell
-3,096
Closed -$257K 175
2023
Q1
$257K Buy
+3,096
New +$256K 0.14% 168
2021
Q1
Sell
-2,088
Closed -$121K 571
2020
Q4
$121K Buy
+2,088
New +$126K 0.07% 278

Other funds holding GILD

Interchange Capital Partners's GILD Position: Q2 2026 in Review

Interchange Capital Partners increased its Gilead Sciences (GILD) stake by 77% in Q2 2026, buying an estimated $308K and bringing the position to 5,395 shares worth $682K. The position accounts for 0.13% of the portfolio, ranked #162.

Interchange Capital Partners first reported a position in GILD in Q4 2020 and has held it in 10 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Interchange Capital Partners held 5,395 shares of Gilead Sciences worth $682K as of Q2 2026.
  • Interchange Capital Partners bought 2,341 Gilead Sciences shares in Q2 2026, an estimated $308K.
  • Gilead Sciences made up 0.13% of Interchange Capital Partners's portfolio in Q2 2026, its #162 holding.
  • Interchange Capital Partners first reported a position in Gilead Sciences in Q4 2020 and has held it in 10 quarters since.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.